2014年9月30日

細胞生物醫藥集團完成收購讚成生物技術有限公司9月30日事故發生2014 ET |來源:細胞生物醫藥集團,帕洛阿爾托,加州9月30日2014(全球通訊社)——細胞生物醫藥集團有限公司(納斯達克:CBMG) (“CBMG”或“公司”),從事生物醫藥公司的發展新的治療退行性疾病和癌症,今天宣布它已經完成了先前宣布收購私人持有讚成中國生物技術有限公司(“公司”)及其創始人的美國專利。AG)的IP由T細胞受體(TCR)單克隆分析技術和中央記憶T細胞(“中醫”)和樹突細胞(DC)製備方法。細胞單克隆分析技術是基於使用多個獨特的引物擴增22集區域的識別,從而檢測克隆擴張相關抗原的刺激免疫係統,使腫瘤特異性免疫的評估精度高和效率。中醫細胞亞群的T淋巴細胞主要特征包括高強度和長時記憶的特定的免疫力;他們immunocellular強化的關鍵因素與腫瘤、感染和免疫紊亂。“收購AG)加速公司的戰略增長癌症免疫細胞治療領域的一個平台,介紹了潛在的補充或取代某些癌症的化療。CBMG計劃擴大公司的業務狀況和成長癌症病人腫瘤特異性免疫評估收入服務更多的醫院。我們熱烈歡迎三十的整合優秀的員工從公司到CBMG家庭。他們還將使CBMG以外擴張其在中國的上海和無錫操作到北部地區,”威廉(魏)曹博士說,細胞生物醫藥集團的首席執行官。根據協議的條款,CBMG將考慮支付約330萬美元的現金和CBMG普通股的發行822522股,一年的鎖定期,日期的協議,以換取所有股票AG)和其創始人的美國專利。 Additional information can be found in the Form 8-K which will be filed by Cellular Biomedicine Group with the Securities and Exchange Commission on or before October 2, 2014. About Cellular Biomedicine Group Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com . Forward-Looking Statements Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law. Sarah KellyDirector of Corporate Communications, CBMG+1 650 566-5064Vivian ChenManaging Director Investor Relations, Grayling+1 646 284-9427 Related Articles other press releases by Cellular Biomedicine Group Inc.